Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04237623 · ClinicalTrials.gov registry record · Phase 2
GM-CSF With Post-Transplant Cyclophosphamide
A Phase 2 study of Transplant-Related Hematologic Malignancy, sponsored by Northside Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04237623 is a Phase 2 study of Transplant-Related Hematologic Malignancy that is actively recruiting participants, run by Northside Hospital. The registered enrollment target is 38 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04237623, a Phase 2 study of Transplant-Related Hematologic Malignancy, is actively recruiting participants, sponsored by Northside Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.
Conditions Studied
Interventions
- OTHER Control Arm
- DRUG Sargramostim
Study Locations (1)
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-05-18 |
| Est. Completion | 2026-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04237623
The ClinicalTrials.gov registry entry for NCT04237623 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transplant-Related Hematologic Malignancy appearing as the primary indexed condition, and to 2 interventions - of which Control Arm is the first listed.
NCT04237623 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04237623 about?
NCT04237623 is a clinical study titled "GM-CSF With Post-Transplant Cyclophosphamide". Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete...
What is the current status of trial NCT04237623?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2020-05-18. Estimated completion is 2026-09-18.
What conditions does trial NCT04237623 study?
This clinical trial studies the following conditions: Transplant-Related Hematologic Malignancy.
What interventions are being tested in trial NCT04237623?
The interventions under investigation include: Control Arm (OTHER), Sargramostim (DRUG).
Who is sponsoring clinical trial NCT04237623?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04237623 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.